<SEC-DOCUMENT>0001193125-25-004117.txt : 20250110
<SEC-HEADER>0001193125-25-004117.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110080028
ACCESSION NUMBER:		0001193125-25-004117
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281937
		FILM NUMBER:		25520498

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d923802d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus
Supplement dated September&nbsp;12, 2024</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>and Prospectus dated September&nbsp;12, 2024)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-281937</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923802g0110054649082.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $1,734,081 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares representing Ordinary Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, or this Supplement, supplements and amends the Prospectus Supplement dated September&nbsp;12, 2024, or the ATM Prospectus
Supplement. This Supplement should be read in conjunction with the ATM Prospectus Supplement and the accompanying prospectus dated September&nbsp;12, 2024, contained in our registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> <FONT
STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-281937)</FONT> filed with the SEC on September&nbsp;5, 2024, or the Registration Statement. This Supplement is qualified by reference to the ATM Prospectus Supplement and the accompanying
prospectus, except to the extent that the information presented herein supersedes the information contained in the ATM Prospectus Supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2022, we entered into an equity distribution agreement, or the Distribution Agreement, with Oppenheimer&nbsp;&amp; Co. Inc., or Oppenheimer,
as amended by an amendment thereto, dated September&nbsp;4, 2024, relating to the sale of our American Depositary Shares, or the ADSs. Each ADS represents 100 fully paid ordinary shares, no par value per ordinary share, or the Ordinary Shares. In
accordance with the terms of the Distribution Agreement, as amended, we may offer and sell ADSs having an aggregate offering price of up to $50,000,000 from time to time through Oppenheimer pursuant to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> transactions. As of the date of this Supplement, we have issued and sold an aggregate of 144,801,800 Ordinary Shares represented by ADSs pursuant to the Distribution Agreement for aggregate
gross proceeds of $13.37&nbsp;million, including an aggregate of 51,641,740 Ordinary Shares represented by ADSs with an aggregate sales price of $1,634,291 under the ATM Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2025, the aggregate market value worldwide of our outstanding voting
<FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> equity held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;was</FONT> approximately US$34.0&nbsp;million, based on 501,736,760 ordinary shares outstanding (which
would be represented by 5,017,367 ADSs assuming all holders held ADSs) held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;as</FONT> of January&nbsp;6, 2025, and a per ADS price of US$6.78 based on the closing sale price of the ADSs on
The Nasdaq Capital Market on November&nbsp;11, 2024. As of the date hereof, we have sold or offered 7,615,905 ADSs for a total of US$5,121,626 pursuant to General Instruction I.B.5 of <FONT STYLE="white-space:nowrap">Form&nbsp;F-3&nbsp;during</FONT>
the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.5 of <FONT STYLE="white-space:nowrap">Form&nbsp;F-3,&nbsp;in</FONT> no event will we sell securities registered on the Registration
Statement of which any prospectus supplement forms a part in a public primary offering with a value <FONT STYLE="white-space:nowrap">exceeding&nbsp;one-third&nbsp;of</FONT> our outstanding voting
<FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> equity held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates,</FONT> or the Public Float, in <FONT STYLE="white-space:nowrap">any&nbsp;12-month&nbsp;period</FONT> so long
as our Public Float remains below US$75.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this Supplement is to reduce the size of the continuous offering by us under the
ATM Prospectus Supplement to up to $1,734,081 of ADSs, effective as of the date hereof. As of the date hereof, after taking into account $1,634,291 of ADSs that we have previously sold under the ATM Prospectus Supplement, we may offer up to
additional $99,790 of ADSs, or Current Limit, under the ATM Prospectus Supplement, as amended by this Supplement, subject to the limit described therein. We will not make any sales of securities exceeding the Current Limit under the ATM Prospectus
Supplement, as amended by the Supplement, unless and until a new prospectus supplement or a new registration statement is filed. The Distribution Agreement, as amended, remains in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADSs representing our ordinary shares are listed on the Nasdaq Capital Market under the symbol &#147;KZIA.&#148; On January&nbsp;8, 2025, the closing sale
price of the ADSs on the Nasdaq Capital Market was $1.69 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in the ADSs
involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-6</FONT> of the ATM Prospectus Supplement, as well as in the
documents incorporated or deemed to be incorporated by reference into the ATM Prospectus Supplement and the accompanying Prospectus, concerning factors you should consider before buying the ADSs. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the ATM
Prospectus Supplement, as amended by this Supplement, and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is January&nbsp;10, 2025. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g923802g0110054649082.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923802g0110054649082.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A 5X# 2(  A$! Q$!_\0
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MQIJ#>PG4BMS>S29K&UW4;BP6V\B6&+S9"K/*,@#%2:/<W-S'))-=VURH("M
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A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
